Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Capecitabine and Oxaliplatin in Rectal Cancer
NCT00297141Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Oct 2004
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Rate of T-downstaging (Reduction of the T-stadium). Started Oct 2004; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00297141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297141.